(Q37400173)
Statements
1 reference
Is there a rationale for the chronic use of phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia? (English)
1 reference
Thierry Roumeguère
1 reference
K Zouaoui Boudjeltia
1 reference
Claude Hauzeur
1 reference
Claude Schulman
1 reference
Michel Vanhaeverbeek
1 reference
Eric Wespes
1 reference
23 February 2009
1 reference
1 reference
104
1 reference
4
1 reference
511-517
1 reference
Identifiers
1 reference
1 reference